Target Audience
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of renal cell carcinoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate recently presented data with adjuvant anti-PD-1/PD-L1 antibody therapy for patients with renal cell carcinoma (RCC) at high risk for recurrence after nephrectomy, and consider the current role of this treatment strategy.
• Effectively apply evidence-based research and other clinical and biological factors in the best-practice selection of first-line therapy for metastatic RCC (mRCC).
• Appraise available clinical trial data evaluating combinations of anti-PD-1/PD-L1 antibodies and multikinase inhibitors for previously untreated mRCC, and counsel patients about the risks and benefits of these novel regimens.
• Review the biological rationale underlying the investigation of combined anti‑PD-1/ anti‑CTLA‑4/multikinase inhibitor therapy as first-line treatment for mRCC, and appreciate available research documenting the effectiveness of this approach.
• Develop a rational approach to the sequencing of systemic therapies for advanced RCC that progresses on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other therapeutic approaches.
• Recognize side effects and toxicities commonly associated with approved and investigational therapeutic approaches, and use this information to develop supportive care plans for patients with RCC undergoing treatment with these agents and regimens.
• Recall available and emerging data with other novel and investigational agents and strategies currently in testing for RCC, and where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit form link will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr McDermott — Consulting Agreements: Bristol Myers Squibb, Clinigen Limited, Exelixis Inc, Iovance Biotherapeutics, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee (Unpaid): RAMPART RCC trial. Dr Pal — Travel: CRISPR Therapeutics, Ipsen Biopharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Aveo Pharmaceuticals and Exelixis Inc.